Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Multiple Sclerosis

  Free Subscription

Articles published in PLoS One

Retrieve available abstracts of 232 articles:
HTML format

Single Articles

    January 2021
  1. JOHNSON DK, Reynolds KM, Poole BD, Montierth MD, et al
    Contribution of viral infection to risk for cancer in systemic lupus erythematosus and multiple sclerosis.
    PLoS One. 2021;16:e0243150.
    PubMed     Abstract available

  2. THALER C, Kyselyova AA, Faizy TD, Nawka MT, et al
    Heterogeneity of multiple sclerosis lesions in fast diffusional kurtosis imaging.
    PLoS One. 2021;16:e0245844.
    PubMed     Abstract available

  3. WILSKI M, Brola W, Luniewska M, Tomczak M, et al
    The perceived impact of multiple sclerosis and self-management: The mediating role of coping strategies.
    PLoS One. 2021;16:e0248135.
    PubMed     Abstract available

  4. GOODIN DS, Khankhanian P, Gourraud PA, Vince N, et al
    The nature of genetic and environmental susceptibility to multiple sclerosis.
    PLoS One. 2021;16:e0246157.
    PubMed     Abstract available

  5. PRIDHAM G, Hossain S, Rawji KS, Zhang Y, et al
    A metric learning method for estimating myelin content based on T2-weighted MRI from a de- and re-myelination model of multiple sclerosis.
    PLoS One. 2021;16:e0249460.
    PubMed     Abstract available

  6. GOUJON A, Mirafzal S, Zuber K, Deschamps R, et al
    3D-Fast Gray Matter Acquisition with Phase Sensitive Inversion Recovery Magnetic Resonance Imaging at 3 Tesla: Application for detection of spinal cord lesions in patients with multiple sclerosis.
    PLoS One. 2021;16:e0247813.
    PubMed     Abstract available

  7. CHOI S, Spini M, Hua J, Harrison DM, et al
    Blood-brain barrier breakdown in non-enhancing multiple sclerosis lesions detected by 7-Tesla MP2RAGE DeltaT1 mapping.
    PLoS One. 2021;16:e0249973.
    PubMed     Abstract available

  8. GOLAN D, Sagiv S, Glass-Marmor L, Miller A, et al
    Mobile-phone-based e-diary derived patient reported outcomes: Association with clinical disease activity, psychological status and quality of life of patients with multiple sclerosis.
    PLoS One. 2021;16:e0250647.
    PubMed     Abstract available

  9. KLISTORNER S, Barnett MH, Wasserthal J, Yiannikas C, et al
    Differentiating axonal loss and demyelination in chronic MS lesions: A novel approach using single streamline diffusivity analysis.
    PLoS One. 2021;16:e0244766.
    PubMed     Abstract available

  10. PAPP V, Buron MD, Siersma V, Rasmussen PV, et al
    Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
    PLoS One. 2021;16:e0250820.
    PubMed     Abstract available

  11. KOENIG KA, Beall EB, Sakaie KE, Ontaneda D, et al
    Evaluation of a connectivity-based imaging metric that reflects functional decline in Multiple Sclerosis.
    PLoS One. 2021;16:e0251338.
    PubMed     Abstract available

  12. CARTER B, Hayes C, Smith A, Pennington A, et al
    A single patient reported outcome measure for acquired brain injury, multiple sclerosis & Parkinson's disease.
    PLoS One. 2021;16:e0251484.
    PubMed     Abstract available

  13. ROGACZEWSKA M, Michalak S, Stopa M
    Macular vessel density differs in multiple sclerosis and neuromyelitis optica spectrum disorder: An optical coherence tomography angiography study.
    PLoS One. 2021;16:e0253417.
    PubMed     Abstract available

    January 2020
  14. HJORTH M, Dandu N, Mellergard J
    Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets.
    PLoS One. 2020;15:e0228380.
    PubMed     Abstract available

  15. GIOVANNETTI AM, Pietrolongo E, Borreani C, Giordano A, et al
    Conversion to secondary progressive multiple sclerosis: Multistakeholder experiences and needs in Italy.
    PLoS One. 2020;15:e0228587.
    PubMed     Abstract available

  16. GRANER M, Pointon T, Manton S, Green M, et al
    Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides.
    PLoS One. 2020;15:e0228883.
    PubMed     Abstract available

  17. SELGRADE BP, Meyer D, Sosnoff JJ, Franz JR, et al
    Can optical flow perturbations detect walking balance impairment in people with multiple sclerosis?
    PLoS One. 2020;15:e0230202.
    PubMed     Abstract available

  18. SECCIA R, Gammelli D, Dominici F, Romano S, et al
    Considering patient clinical history impacts performance of machine learning models in predicting course of multiple sclerosis.
    PLoS One. 2020;15:e0230219.
    PubMed     Abstract available

  19. AKAISHI T, Takahashi T, Fujihara K, Misu T, et al
    Number of MRI T1-hypointensity corrected by T2/FLAIR lesion volume indicates clinical severity in patients with multiple sclerosis.
    PLoS One. 2020;15:e0231225.
    PubMed     Abstract available

  20. BARRERO F, Mallada-Frechin J, Martinez-Gines ML, Marzo ME, et al
    Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.
    PLoS One. 2020;15:e0230846.
    PubMed     Abstract available

  21. GIOVANNETTI AM, Quintas R, Tramacere I, Giordano A, et al
    A resilience group training program for people with multiple sclerosis: Results of a pilot single-blind randomized controlled trial and nested qualitative study.
    PLoS One. 2020;15:e0231380.
    PubMed     Abstract available

  22. SILVA T, Fragoso YD, Destro Rodrigues MFS, Gomes AO, et al
    Effects of photobiomodulation on interleukin-10 and nitrites in individuals with relapsing-remitting multiple sclerosis - Randomized clinical trial.
    PLoS One. 2020;15:e0230551.
    PubMed     Abstract available

  23. HASHEMI R, Hosseini-Asl SS, Arefhosseini SR, Morshedi M, et al
    The impact of vitamin D3 intake on inflammatory markers in multiple sclerosis patients and their first-degree relatives.
    PLoS One. 2020;15:e0231145.
    PubMed     Abstract available

  24. MASUDA H, Mori M, Uzawa A, Uchida T, et al
    Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis.
    PLoS One. 2020;15:e0224419.
    PubMed     Abstract available

  25. PARRAVICINI C, Lecca D, Marangon D, Coppolino GT, et al
    Development of the first in vivo GPR17 ligand through an iterative drug discovery pipeline: A novel disease-modifying strategy for multiple sclerosis.
    PLoS One. 2020;15:e0231483.
    PubMed     Abstract available

  26. GOITIA B, Bruno D, Abrevaya S, Sedeno L, et al
    The relationship between executive functions and fluid intelligence in multiple sclerosis.
    PLoS One. 2020;15:e0231868.
    PubMed     Abstract available

  27. SAURI-SUAREZ S, Quinones-Aguilar S, Contreras-Marin A, Ramiro-Guerrero EO, et al
    Adherence to self-administering interferon-beta1a using RebiSmart(R) device in Mexican patients with relapsing multiple sclerosis.
    PLoS One. 2020;15:e0230959.
    PubMed     Abstract available

  28. OHLMEIER C, Gothe H, Haas J, Osowski U, et al
    Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data.
    PLoS One. 2020;15:e0231846.
    PubMed     Abstract available

  29. GOUGH N, Brkan L, Subramaniam P, Chiuccariello L, et al
    Feasibility of remotely supervised transcranial direct current stimulation and cognitive remediation: A systematic review.
    PLoS One. 2020;15:e0223029.
    PubMed     Abstract available

  30. GOLDMAN MD, Dwyer L, Coleman R, Sohn MW, et al
    Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients.
    PLoS One. 2020;15:e0228617.
    PubMed     Abstract available

  31. KUSNIEROVA P, Zeman D, Hradilek P, Zapletalova O, et al
    Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases.
    PLoS One. 2020;15:e0233519.
    PubMed     Abstract available

  32. BROWN FS, Glasmacher SA, Kearns PKA, MacDougall N, et al
    Systematic review of prediction models in relapsing remitting multiple sclerosis.
    PLoS One. 2020;15:e0233575.
    PubMed     Abstract available

  33. BAUER A, Lechner I, Auer M, Berger T, et al
    Influence of physical activity on serum vitamin D levels in people with multiple sclerosis.
    PLoS One. 2020;15:e0234333.
    PubMed     Abstract available

  34. LUCCHETTA RC, Leonart LP, Goncalves MVM, Becker J, et al
    Reliability in long-term clinical studies of disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review.
    PLoS One. 2020;15:e0231722.
    PubMed     Abstract available

  35. JULIAN GS, Rosim RP, Carneseca EC, Rigolon J, et al
    Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach.
    PLoS One. 2020;15:e0229768.
    PubMed     Abstract available

  36. CHERAGHMAKANI H, Baghbanian SM, HabibiSaravi R, Azar A, et al
    Age and sex-adjusted incidence and yearly prevalence of multiple sclerosis (MS) in Mazandaran province, Iran: An 11-years study.
    PLoS One. 2020;15:e0235562.
    PubMed     Abstract available

  37. ROTSTEIN DL, Marrie RA, Tu K, Schultz SE, et al
    Health service utilization in immigrants with multiple sclerosis.
    PLoS One. 2020;15:e0234876.
    PubMed     Abstract available

  38. NINOU I, Sevastou I, Magkrioti C, Kaffe E, et al
    Genetic deletion of Autotaxin from CD11b+ cells decreases the severity of experimental autoimmune encephalomyelitis.
    PLoS One. 2020;15:e0226050.
    PubMed     Abstract available

  39. FARCI R, Carta A, Cocco E, Frau J, et al
    Optical coherence tomography angiography in multiple sclerosis: A cross-sectional study.
    PLoS One. 2020;15:e0236090.
    PubMed     Abstract available

  40. ILJICSOV A, Milanovich D, Ajtay A, Oberfrank F, et al
    Incidence and prevalence of multiple sclerosis in Hungary based on record linkage of nationwide multiple healthcare administrative data.
    PLoS One. 2020;15:e0236432.
    PubMed     Abstract available

  41. KEMMERER CL, Pernpeintner V, Ruschil C, Abdelhak A, et al
    Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-beta, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
    PLoS One. 2020;15:e0235449.
    PubMed     Abstract available

  42. CAVERZASI E, Cordano C, Zhu AH, Zhao C, et al
    Imaging correlates of visual function in multiple sclerosis.
    PLoS One. 2020;15:e0235615.
    PubMed     Abstract available

  43. PAMPHLETT R, Mak R, Lee J, Buckland ME, et al
    Concentrations of toxic metals and essential trace elements vary among individual neurons in the human locus ceruleus.
    PLoS One. 2020;15:e0233300.
    PubMed     Abstract available

  44. SINHA S, Renavikar PS, Crawford MP, Steward-Tharp SM, et al
    Altered expression of SIRPgamma on the T-cells of relapsing remitting multiple sclerosis and type 1 diabetes patients could potentiate effector responses from T-cells.
    PLoS One. 2020;15:e0238070.
    PubMed     Abstract available

  45. MORALES PANTOJA IE, Smith MD, Rajbhandari L, Cheng L, et al
    iPSCs from people with MS can differentiate into oligodendrocytes in a homeostatic but not an inflammatory milieu.
    PLoS One. 2020;15:e0233980.
    PubMed     Abstract available

  46. SOUZA KM, Diniz IM, Lemos LLP, Junior NGR, et al
    Effectiveness of first-line treatment for relapsing-remitting multiple sclerosis in Brazil: A 16-year non-concurrent cohort study.
    PLoS One. 2020;15:e0238476.
    PubMed     Abstract available

  47. ALNAJASHI H, Jabbad R
    Behavioral practices of patients with multiple sclerosis during Covid-19 pandemic.
    PLoS One. 2020;15:e0241103.
    PubMed     Abstract available

  48. COTTRELL L, Economos G, Evans C, Silber E, et al
    A realist review of advance care planning for people with multiple sclerosis and their families.
    PLoS One. 2020;15:e0240815.
    PubMed     Abstract available

  49. MELNIKOV M, Sharanova S, Sviridova A, Rogovskii V, et al
    The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.
    PLoS One. 2020;15:e0240305.
    PubMed     Abstract available

  50. PERLEJEWSKI K, Bukowska-Osko I, Rydzanicz M, Dzieciatkowski T, et al
    Search for viral agents in cerebrospinal fluid in patients with multiple sclerosis using real-time PCR and metagenomics.
    PLoS One. 2020;15:e0240601.
    PubMed     Abstract available

  51. ZHANG X, Gao B, Xu B
    No association between the vitamin D-binding protein (DBP) gene polymorphisms (rs7041 and rs4588) and multiple sclerosis and type 1 diabetes mellitus: A meta-analysis.
    PLoS One. 2020;15:e0242256.
    PubMed     Abstract available

  52. BEREK K, Hegen H, Auer M, Zinganell A, et al
    Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi.
    PLoS One. 2020;15:e0239453.
    PubMed     Abstract available

  53. NIKOLIC B, Ivancevic N, Zaletel I, Rovcanin B, et al
    Characteristics of pediatric multiple sclerosis: A tertiary referral center study.
    PLoS One. 2020;15:e0243031.
    PubMed     Abstract available

  54. CORDON B, Vilades E, Orduna E, Satue M, et al
    Angiography with optical coherence tomography as a biomarker in multiple sclerosis.
    PLoS One. 2020;15:e0243236.
    PubMed     Abstract available

  55. VICKARYOUS N, Jitlal M, Jacobs BM, Middleton R, et al
    Remote testing of vitamin D levels across the UK MS population-A case control study.
    PLoS One. 2020;15:e0241459.
    PubMed     Abstract available

    January 2019
  56. DUQUETTE P, Yeung M, Mouallif S, Nakhaipour HR, et al
    A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies.
    PLoS One. 2019;14:e0210417.
    PubMed     Abstract available

  57. FRAHM N, Hecker M, Zettl UK
    Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: A single-center study.
    PLoS One. 2019;14:e0211120.
    PubMed     Abstract available

  58. KOBELT G, Teich V, Cavalcanti M, Canzonieri AM, et al
    Burden and cost of multiple sclerosis in Brazil.
    PLoS One. 2019;14:e0208837.
    PubMed     Abstract available

  59. NOCITI V, Santoro M, Quaranta D, Losavio FA, et al
    Correction: BDNF rs6265 polymorphism methylation in Multiple Sclerosis: A possible marker of disease progression.
    PLoS One. 2019;14:e0212906.
    PubMed     Abstract available

  60. PATRICK S, Connick P
    Psychometric properties of the PHQ-9 depression scale in people with multiple sclerosis: A systematic review.
    PLoS One. 2019;14:e0197943.
    PubMed     Abstract available

  61. NEATE SL, Taylor KL, Jelinek GA, De Livera AM, et al
    Taking active steps: Changes made by partners of people with multiple sclerosis who undertake lifestyle modification.
    PLoS One. 2019;14:e0212422.
    PubMed     Abstract available

  62. GIROLAMO F, Errede M, Longo G, Annese T, et al
    Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice.
    PLoS One. 2019;14:e0213508.
    PubMed     Abstract available

  63. DE SANTIAGO L, Sanchez Morla EM, Ortiz M, Lopez E, et al
    A computer-aided diagnosis of multiple sclerosis based on mfVEP recordings.
    PLoS One. 2019;14:e0214662.
    PubMed     Abstract available

  64. HOGESTOL EA, Nygaard GO, Alnaes D, Beyer MK, et al
    Symptoms of fatigue and depression is reflected in altered default mode network connectivity in multiple sclerosis.
    PLoS One. 2019;14:e0210375.
    PubMed     Abstract available

  65. AZAMI M, YektaKooshali MH, Shohani M, Khorshidi A, et al
    Epidemiology of multiple sclerosis in Iran: A systematic review and meta-analysis.
    PLoS One. 2019;14:e0214738.
    PubMed     Abstract available

  66. PEREZ DEL PALOMAR A, Cegonino J, Montolio A, Orduna E, et al
    Swept source optical coherence tomography to early detect multiple sclerosis disease. The use of machine learning techniques.
    PLoS One. 2019;14:e0216410.
    PubMed     Abstract available

  67. ALOWAYESH MS, Ahmed SF, Al-Hashel J, Alroughani R, et al
    Economic burden of multiple sclerosis on Kuwait health care system.
    PLoS One. 2019;14:e0216646.
    PubMed     Abstract available

  68. BEDRI SK, Nilsson OB, Fink K, Manberg A, et al
    Plasma protein profiling reveals candidate biomarkers for multiple sclerosis treatment.
    PLoS One. 2019;14:e0217208.
    PubMed     Abstract available

  69. EVDOSHENKO E, Stepanova A, Shumilina M, Davydovskaya M, et al
    Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia.
    PLoS One. 2019;14:e0217303.
    PubMed     Abstract available

  70. MARRIE RA, O'Mahony J, Maxwell CJ, Ling V, et al
    High rates of health care utilization in pediatric multiple sclerosis: A Canadian population-based study.
    PLoS One. 2019;14:e0218215.
    PubMed     Abstract available

  71. FELLOWS MAXWELL K, Wahls T, Browne RW, Rubenstein L, et al
    Lipid profile is associated with decreased fatigue in individuals with progressive multiple sclerosis following a diet-based intervention: Results from a pilot study.
    PLoS One. 2019;14:e0218075.
    PubMed     Abstract available

  72. AZAMI M, YektaKooshali MH, Shohani M, Khorshidi A, et al
    Correction: Epidemiology of multiple sclerosis in Iran: A systematic review and meta-analysis.
    PLoS One. 2019;14:e0219466.
    PubMed     Abstract available

  73. VAZQUEZ-MARRUFO M, Galvao-Carmona A, Caballero-Diaz R, Borges M, et al
    Altered individual behavioral and EEG parameters are related to the EDSS score in relapsing-remitting multiple sclerosis patients.
    PLoS One. 2019;14:e0219594.
    PubMed     Abstract available

  74. RO LS, Yang CC, Lyu RK, Lin KP, et al
    A prospective, observational study on conversion of clinically isolated syndrome to multiple sclerosis during 4-year period (MS NEO study) in Taiwan.
    PLoS One. 2019;14:e0202453.
    PubMed     Abstract available

  75. EHLING R, Bsteh G, Muehlbacher A, Hermann K, et al
    Ecological validity of walking capacity tests following rehabilitation in people with multiple sclerosis.
    PLoS One. 2019;14:e0220613.
    PubMed     Abstract available

  76. GRIMALDI AE, De Giglio L, Haggiag S, Bianco A, et al
    The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray).
    PLoS One. 2019;14:e0219670.
    PubMed     Abstract available

  77. HAREL Y, Kalron A, Menascu S, Magalashvili D, et al
    Cognitive function in multiple sclerosis: A long-term look on the bright side.
    PLoS One. 2019;14:e0221784.
    PubMed     Abstract available

  78. ISMAILOVA K, Poudel P, Parlesak A, Frederiksen P, et al
    Vitamin D in early life and later risk of multiple sclerosis-A systematic review, meta-analysis.
    PLoS One. 2019;14:e0221645.
    PubMed     Abstract available

  79. SHI J, Wu X, Chen Y
    Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis.
    PLoS One. 2019;14:e0222288.
    PubMed     Abstract available

  80. LIN SD, Butler JE, Boswell-Ruys CL, Hoang P, et al
    The frequency of bowel and bladder problems in multiple sclerosis and its relation to fatigue: A single centre experience.
    PLoS One. 2019;14:e0222731.
    PubMed     Abstract available

  81. MOCCIA M, Tajani A, Acampora R, Signoriello E, et al
    Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery.
    PLoS One. 2019;14:e0222012.
    PubMed     Abstract available

  82. JONGEN PJ, van Mastrigt GA, Heerings M, Visser LH, et al
    Effect of an intensive 3-day social cognitive treatment (can do treatment) on control self-efficacy in patients with relapsing remitting multiple sclerosis and low disability: A single-centre randomized controlled trial.
    PLoS One. 2019;14:e0223482.
    PubMed     Abstract available

  83. AMATO MP, Prestipino E, Bellinvia A, Niccolai C, et al
    Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors.
    PLoS One. 2019;14:e0222929.
    PubMed     Abstract available

  84. WORMSBECKER AE, Johnson C, Bourns L, Harris T, et al
    Demonstration of background rates of three conditions of interest for vaccine safety surveillance.
    PLoS One. 2019;14:e0210833.
    PubMed     Abstract available

  85. AMATO MP, Prestipino E, Bellinvia A, Niccolai C, et al
    Correction: Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors.
    PLoS One. 2019;14:e0225494.
    PubMed     Abstract available

  86. BOQUETE L, Lopez-Guillen E, Vilades E, Miguel-Jimenez JM, et al
    Diagnostic ability of multifocal electroretinogram in early multiple sclerosis using a new signal analysis method.
    PLoS One. 2019;14:e0224500.
    PubMed     Abstract available

  87. CORTINI A, Bembich S, Marson L, Cocco E, et al
    Identification of novel non-myelin biomarkers in multiple sclerosis using an improved phage-display approach.
    PLoS One. 2019;14:e0226162.
    PubMed     Abstract available

  88. BURKILL S, Vattulainen P, Geissbuehler Y, Sabido Espin M, et al
    The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis.
    PLoS One. 2019;14:e0227120.
    PubMed     Abstract available

  89. EHLING R, Amprosi M, Kremmel B, Bsteh G, et al
    Second language learning induces grey matter volume increase in people with multiple sclerosis.
    PLoS One. 2019;14:e0226525.
    PubMed     Abstract available

  90. POSTIGO-ALONSO B, Galvao-Carmona A, Conde-Gavilan C, Jover A, et al
    The effect of prioritization over cognitive-motor interference in people with relapsing-remitting multiple sclerosis and healthy controls.
    PLoS One. 2019;14:e0226775.
    PubMed     Abstract available

  91. MELIS M, Littera R, Cocco E, Frau J, et al
    Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: A pilot study on multiple sclerosis.
    PLoS One. 2019;14:e0226615.
    PubMed     Abstract available

  92. LEE SU, Li CF, Mortales CL, Pawling J, et al
    Increasing cell permeability of N-acetylglucosamine via 6-acetylation enhances capacity to suppress T-helper 1 (TH1)/TH17 responses and autoimmunity.
    PLoS One. 2019;14:e0214253.
    PubMed     Abstract available

  93. TEMPLETON N, Kivell B, McCaughey-Chapman A, Connor B, et al
    Clozapine administration enhanced functional recovery after cuprizone demyelination.
    PLoS One. 2019;14:e0216113.
    PubMed     Abstract available

  94. LANDTBLOM AM, Guala D, Martin C, Olsson-Hau S, et al
    RebiQoL: A randomized trial of telemedicine patient support program for health-related quality of life and adherence in people with MS treated with Rebif.
    PLoS One. 2019;14:e0218453.
    PubMed     Abstract available

  95. GAJAMANGE S, Shelton A, Clough M, White O, et al
    Functional correlates of cognitive dysfunction in clinically isolated syndromes.
    PLoS One. 2019;14:e0219590.
    PubMed     Abstract available

  96. KAPICA-TOPCZEWSKA K, Tarasiuk J, Collin F, Brola W, et al
    The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.
    PLoS One. 2019;14:e0223863.
    PubMed     Abstract available

    January 2018
  97. AGAH E, Zardoui A, Saghazadeh A, Ahmadi M, et al
    Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0190252.
    PubMed     Abstract available

  98. WANG C, Klistorner A, Ly L, Barnett MH, et al
    White matter tract-specific quantitative analysis in multiple sclerosis: Comparison of optic radiation reconstruction techniques.
    PLoS One. 2018;13:e0191131.
    PubMed     Abstract available

  99. LAVTAR P, Rudolf G, Maver A, Hodzic A, et al
    Association of circadian rhythm genes ARNTL/BMAL1 and CLOCK with multiple sclerosis.
    PLoS One. 2018;13:e0190601.
    PubMed     Abstract available

  100. BEGGS CB, Giaquinta A, Veroux M, De Marco E, et al
    Mid-term sustained relief from headaches after balloon angioplasty of the internal jugular veins in patients with multiple sclerosis.
    PLoS One. 2018;13:e0191534.
    PubMed     Abstract available

  101. CALOCER F, Dejardin O, Droulon K, Launoy G, et al
    Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients.
    PLoS One. 2018;13:e0191646.
    PubMed     Abstract available

  102. CHARVET LE, Yang J, Shaw MT, Sherman K, et al
    Correction: Cognitive function in multiple sclerosis improves with telerehabilitation: Results from a randomized controlled trial.
    PLoS One. 2018;13:e0192317.
    PubMed     Abstract available

  103. DE FLON P, Soderstrom L, Laurell K, Dring A, et al
    Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls.
    PLoS One. 2018;13:e0192516.
    PubMed     Abstract available

  104. HASSANI A, Corboy JR, Al-Salam S, Khan G, et al
    Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells.
    PLoS One. 2018;13:e0192109.
    PubMed     Abstract available

  105. GOODIN DS, Khankhanian P, Gourraud PA, Vince N, et al
    Highly conserved extended haplotypes of the major histocompatibility complex and their relationship to multiple sclerosis susceptibility.
    PLoS One. 2018;13:e0190043.
    PubMed     Abstract available

  106. DENNISON L, Brown M, Kirby S, Galea I, et al
    Do people with multiple sclerosis want to know their prognosis? A UK nationwide study.
    PLoS One. 2018;13:e0193407.
    PubMed     Abstract available

  107. KHAN A, Kamran S, Ponirakis G, Akhtar N, et al
    Peripheral neuropathy in patients with multiple sclerosis.
    PLoS One. 2018;13:e0193270.
    PubMed     Abstract available

  108. BAGNATO F, Hametner S, Boyd E, Endmayr V, et al
    Untangling the R2* contrast in multiple sclerosis: A combined MRI-histology study at 7.0 Tesla.
    PLoS One. 2018;13:e0193839.
    PubMed     Abstract available

  109. NARDIN C, Latarche C, Soudant M, Dahan C, et al
    Generational changes in multiple sclerosis phenotype in North African immigrants in France: A population-based observational study.
    PLoS One. 2018;13:e0194115.
    PubMed     Abstract available

  110. NOVAKOVA L, Axelsson M, Malmestrom C, Imberg H, et al
    Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers.
    PLoS One. 2018;13:e0194828.
    PubMed     Abstract available

  111. KOZIARSKA D, Krol J, Nocon D, Kubaszewski P, et al
    Prevalence and factors leading to unemployment in MS (multiple sclerosis) patients undergoing immunomodulatory treatment in Poland.
    PLoS One. 2018;13:e0194117.
    PubMed     Abstract available

  112. DE SANTIAGO L, Sanchez-Morla E, Blanco R, Miguel JM, et al
    Empirical mode decomposition processing to improve multifocal-visual-evoked-potential signal analysis in multiple sclerosis.
    PLoS One. 2018;13:e0194964.
    PubMed     Abstract available

  113. CIURLEO R, Bonanno L, De Salvo S, Romeo L, et al
    Olfactory dysfunction as a prognostic marker for disability progression in Multiple Sclerosis: An olfactory event related potential study.
    PLoS One. 2018;13:e0196006.
    PubMed     Abstract available

  114. SANCHEZ-DALMAU B, Martinez-Lapiscina EH, Pulido-Valdeolivas I, Zubizarreta I, et al
    Predictors of vision impairment in Multiple Sclerosis.
    PLoS One. 2018;13:e0195856.
    PubMed     Abstract available

  115. KLISTORNER A, Wang C, Yiannikas C, Parratt J, et al
    Diffusivity in the core of chronic multiple sclerosis lesions.
    PLoS One. 2018;13:e0194142.
    PubMed     Abstract available

  116. CHROBOK NL, Bol JGJM, Jongenelen CA, Breve JJP, et al
    Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
    PLoS One. 2018;13:e0196433.
    PubMed     Abstract available

  117. ABDOLLAHPOUR I, Nedjat S, Mansournia MA, Schuster T, et al
    Estimation of the marginal effect of regular drug use on multiple sclerosis in the Iranian population.
    PLoS One. 2018;13:e0196244.
    PubMed     Abstract available

  118. Correction: Empirical mode decomposition processing to improve multifocal-visual-evoked-potential signal analysis in multiple sclerosis.
    PLoS One. 2018;13:e0196928.
    PubMed     Abstract available

  119. STORM FA, Nair KPS, Clarke AJ, Van der Meulen JM, et al
    Free-living and laboratory gait characteristics in patients with multiple sclerosis.
    PLoS One. 2018;13:e0196463.
    PubMed     Abstract available

  120. FERNANDEZ O, Izquierdo G, Fernandez V, Leyva L, et al
    Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.
    PLoS One. 2018;13:e0195891.
    PubMed     Abstract available

  121. SCOTTI B, Disanto G, Sacco R, Guigli M, et al
    Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland.
    PLoS One. 2018;13:e0197415.
    PubMed     Abstract available

  122. MARCK CH, De Livera AM, Brown CR, Neate SL, et al
    Health outcomes and adherence to a healthy lifestyle after a multimodal intervention in people with multiple sclerosis: Three year follow-up.
    PLoS One. 2018;13:e0197759.
    PubMed     Abstract available

  123. POTTGEN J, Rose A, van de Vis W, Engelbrecht J, et al
    Sexual dysfunctions in MS in relation to neuropsychiatric aspects and its psychological treatment: A scoping review.
    PLoS One. 2018;13:e0193381.
    PubMed     Abstract available

  124. ADUSUMILLI G, Lancia S, Levasseur VA, Amblee V, et al
    Turning is an important marker of balance confidence and walking limitation in persons with multiple sclerosis.
    PLoS One. 2018;13:e0198178.
    PubMed     Abstract available

  125. MAIA DINIZ I, Guerra AA Junior, Lovato Pires de Lemos L, Souza KM, et al
    The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil.
    PLoS One. 2018;13:e0199446.
    PubMed     Abstract available

  126. PARKER HARP CR, Archambault AS, Sim J, Shlomchik MJ, et al
    B cells are capable of independently eliciting rapid reactivation of encephalitogenic CD4 T cells in a murine model of multiple sclerosis.
    PLoS One. 2018;13:e0199694.
    PubMed     Abstract available

  127. RAHIMI F, Rasekh HR, Abbasian E, Peiravian F, et al
    Patient preferences for Interferon-beta in Iran: A discrete choice experiment.
    PLoS One. 2018;13:e0193090.
    PubMed     Abstract available

  128. GIOVANNETTI AM, Borreani C, Bianchi E, Giordano A, et al
    Participant perspectives of a home-based palliative approach for people with severe multiple sclerosis: A qualitative study.
    PLoS One. 2018;13:e0200532.
    PubMed     Abstract available

  129. KODA T, Namba A, Nakatsuji Y, Niino M, et al
    Beneficial effects of fingolimod in MS patients with high serum Sema4A levels.
    PLoS One. 2018;13:e0193986.
    PubMed     Abstract available

  130. WUERFEL E, Weddige A, Hagmayer Y, Jacob R, et al
    Cognitive deficits including executive functioning in relation to clinical parameters in paediatric MS patients.
    PLoS One. 2018;13:e0194873.
    PubMed     Abstract available

  131. KANG Y, Schlyer D, Kaunzner UW, Kuceyeski A, et al
    Comparison of two different methods of image analysis for the assessment of microglial activation in patients with multiple sclerosis using (R)-[N-methyl-carbon-11]PK11195.
    PLoS One. 2018;13:e0201289.
    PubMed     Abstract available

  132. MARTIN NA, Nawrocki A, Molnar V, Elkjaer ML, et al
    Orthologous proteins of experimental de- and remyelination are differentially regulated in the CSF proteome of multiple sclerosis subtypes.
    PLoS One. 2018;13:e0202530.
    PubMed     Abstract available

  133. MOKHTARZADEH KHANGHAHI A, Satarian L, Deng W, Baharvand H, et al
    In vivo conversion of astrocytes into oligodendrocyte lineage cells with transcription factor Sox10; Promise for myelin repair in multiple sclerosis.
    PLoS One. 2018;13:e0203785.
    PubMed     Abstract available

  134. CHAWLA S, Kister I, Sinnecker T, Wuerfel J, et al
    Longitudinal study of multiple sclerosis lesions using ultra-high field (7T) multiparametric MR imaging.
    PLoS One. 2018;13:e0202918.
    PubMed     Abstract available

  135. LASO-GARCIA F, Ramos-Cejudo J, Carrillo-Salinas FJ, Otero-Ortega L, et al
    Therapeutic potential of extracellular vesicles derived from human mesenchymal stem cells in a model of progressive multiple sclerosis.
    PLoS One. 2018;13:e0202590.
    PubMed     Abstract available

  136. GRACIA F, Larreategui M, Rodriguez G, Benzadon A, et al
    Costs of multiple sclerosis in Panama from societal, patient perspectives and health-related quality of life.
    PLoS One. 2018;13:e0204681.
    PubMed     Abstract available

  137. SVOLGAARD O, Andersen KW, Bauer C, Madsen KH, et al
    Cerebellar and premotor activity during a non-fatiguing grip task reflects motor fatigue in relapsing-remitting multiple sclerosis.
    PLoS One. 2018;13:e0201162.
    PubMed     Abstract available

  138. NOCITI V, Santoro M, Quaranta D, Losavio FA, et al
    BDNF rs6265 polymorphism methylation in Multiple Sclerosis: A possible marker of disease progression.
    PLoS One. 2018;13:e0206140.
    PubMed     Abstract available

  139. SCHEIDLER AM, Kinnett-Hopkins D, Learmonth YC, Motl R, et al
    Targeted ballet program mitigates ataxia and improves balance in females with mild-to-moderate multiple sclerosis.
    PLoS One. 2018;13:e0205382.
    PubMed     Abstract available

  140. RHEAD B, Brorson IS, Berge T, Adams C, et al
    Increased DNA methylation of SLFN12 in CD4+ and CD8+ T cells from multiple sclerosis patients.
    PLoS One. 2018;13:e0206511.
    PubMed     Abstract available

  141. CHU R, Kim G, Tauhid S, Khalid F, et al
    Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines.
    PLoS One. 2018;13:e0206939.
    PubMed     Abstract available

  142. GIORDANO A, Liethmann K, Kopke S, Poettgen J, et al
    Risk knowledge of people with relapsing-remitting multiple sclerosis - Results of an international survey.
    PLoS One. 2018;13:e0208004.
    PubMed     Abstract available

  143. PAWLITZKI M, Sweeney-Reed CM, Meuth SG, Reinhold D, et al
    CSF macrophage migration inhibitory factor levels did not predict steroid treatment response after optic neuritis in patients with multiple sclerosis.
    PLoS One. 2018;13:e0207726.
    PubMed     Abstract available

  144. CHROBOK NL, Bol JGJM, Jongenelen CA, Breve JJP, et al
    Correction: Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
    PLoS One. 2018;13:e0209522.
    PubMed     Abstract available

  145. KOSKIMAKI F, Bernard J, Yong J, Arndt N, et al
    Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.
    PLoS One. 2018;13:e0209326.
    PubMed     Abstract available

  146. POPESCU DC, Huang H, Singhal NK, Shriver L, et al
    Vitamin K enhances the production of brain sulfatides during remyelination.
    PLoS One. 2018;13:e0203057.
    PubMed     Abstract available

  147. KALKOWSKI L, Malysz-Cymborska I, Golubczyk D, Janowski M, et al
    MRI-guided intracerebral convection-enhanced injection of gliotoxins to induce focal demyelination in swine.
    PLoS One. 2018;13:e0204650.
    PubMed     Abstract available

  148. UGARTE-BERZAL E, Berghmans N, Boon L, Martens E, et al
    Gelatinase B/matrix metalloproteinase-9 is a phase-specific effector molecule, independent from Fas, in experimental autoimmune encephalomyelitis.
    PLoS One. 2018;13:e0197944.
    PubMed     Abstract available

    January 2017
  149. MOCCIA M, Palladino R, Lanzillo R, Carotenuto A, et al
    Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015.
    PLoS One. 2017;12:e0169489.
    PubMed     Abstract available

  150. BROCHET B, Deloire MS, Perez P, Loock T, et al
    Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis.
    PLoS One. 2017;12:e0168834.
    PubMed     Abstract available

  151. LIBERTINOVA J, Meluzinova E, Tomek A, Horakova D, et al
    Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNbeta.
    PLoS One. 2017;12:e0169957.
    PubMed     Abstract available

  152. RAFFEL J, Gafson AR, Dahdaleh S, Malik O, et al
    Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis.
    PLoS One. 2017;12:e0169546.
    PubMed     Abstract available

  153. KAVALIUNAS A, Manouchehrinia A, Danylaite Karrenbauer V, Gyllensten H, et al
    Income in Multiple Sclerosis Patients with Different Disease Phenotypes.
    PLoS One. 2017;12:e0169460.
    PubMed     Abstract available

  154. HURTADO-GUERRERO I, Pinto-Medel MJ, Urbaneja P, Rodriguez-Bada JL, et al
    Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNss in Multiple Sclerosis Patients According to the Therapeutic Response to IFNss.
    PLoS One. 2017;12:e0170031.
    PubMed     Abstract available

  155. UECKER FC, Olze H, Kunte H, Gerz C, et al
    Longitudinal Testing of Olfactory and Gustatory Function in Patients with Multiple Sclerosis.
    PLoS One. 2017;12:e0170492.
    PubMed     Abstract available

  156. ZOU L, Wang H, Xiao Z, Fang Q, et al
    Tai chi for health benefits in patients with multiple sclerosis: A systematic review.
    PLoS One. 2017;12:e0170212.
    PubMed     Abstract available

  157. MOON Y, McGinnis RS, Seagers K, Motl RW, et al
    Monitoring gait in multiple sclerosis with novel wearable motion sensors.
    PLoS One. 2017;12:e0171346.
    PubMed     Abstract available

  158. LINK J, Ramanujam R, Auer M, Ryner M, et al
    Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.
    PLoS One. 2017;12:e0170395.
    PubMed     Abstract available

  159. MORANDI E, Tanasescu R, Tarlinton RE, Constantinescu CS, et al
    The association between human endogenous retroviruses and multiple sclerosis: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0172415.
    PubMed     Abstract available

  160. BEHBEHANI R, Abu Al-Hassan A, Al-Salahat A, Sriraman D, et al
    Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis.
    PLoS One. 2017;12:e0172120.
    PubMed     Abstract available

  161. FAIZY TD, Thaler C, Ceyrowski T, Broocks G, et al
    Reliability of cortical lesion detection on double inversion recovery MRI applying the MAGNIMS-Criteria in multiple sclerosis patients within a 16-months period.
    PLoS One. 2017;12:e0172923.
    PubMed     Abstract available

  162. KOMEGAE EN, Souza TA, Grund LZ, Lima C, et al
    Multiple functional therapeutic effects of TnP: A small stable synthetic peptide derived from fish venom in a mouse model of multiple sclerosis.
    PLoS One. 2017;12:e0171796.
    PubMed     Abstract available

  163. WENDEBOURG MJ, Heesen C, Finlayson M, Meyer B, et al
    Patient education for people with multiple sclerosis-associated fatigue: A systematic review.
    PLoS One. 2017;12:e0173025.
    PubMed     Abstract available

  164. MULS N, Nasr Z, Dang HA, Sindic C, et al
    IL-22, GM-CSF and IL-17 in peripheral CD4+ T cell subpopulations during multiple sclerosis relapses and remission. Impact of corticosteroid therapy.
    PLoS One. 2017;12:e0173780.
    PubMed     Abstract available

  165. HEGEN H, Auer M, Bsteh G, Di Pauli F, et al
    Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study.
    PLoS One. 2017;12:e0174005.
    PubMed     Abstract available

  166. AYUSO T, Aznar P, Soriano L, Olaskoaga A, et al
    Vitamin D receptor gene is epigenetically altered and transcriptionally up-regulated in multiple sclerosis.
    PLoS One. 2017;12:e0174726.
    PubMed     Abstract available

  167. GIESS RM, Pfuhl C, Behrens JR, Rasche L, et al
    Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis.
    PLoS One. 2017;12:e0175279.
    PubMed     Abstract available

  168. DOBRAKOWSKI P, Bogocz M, Cholewa K, Rajchel M, et al
    Month of birth and level of insolation as risk factors for multiple sclerosis in Poland.
    PLoS One. 2017;12:e0175156.
    PubMed     Abstract available

  169. ZHAO Y, Healy BC, Rotstein D, Guttmann CR, et al
    Exploration of machine learning techniques in predicting multiple sclerosis disease course.
    PLoS One. 2017;12:e0174866.
    PubMed     Abstract available

  170. KRAMER J, Tenberge JG, Kleiter I, Gaissmaier W, et al
    Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
    PLoS One. 2017;12:e0174858.
    PubMed     Abstract available

  171. SHARMA S, Zhang Y
    Fourier transform power spectrum is a potential measure of tissue alignment in standard MRI: A multiple sclerosis study.
    PLoS One. 2017;12:e0175979.
    PubMed     Abstract available

  172. NAVAS-MADRONAL M, Valero-Mut A, Martinez-Zapata MJ, Simon-Talero MJ, et al
    Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review.
    PLoS One. 2017;12:e0175538.
    PubMed     Abstract available

  173. SCHNEIDER R, Bellenberg B, Hoepner R, Kolb EM, et al
    Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML).
    PLoS One. 2017;12:e0176415.
    PubMed     Abstract available

  174. INGLESE M, Petracca M, Mormina E, Achiron A, et al
    Cerebellar volume as imaging outcome in progressive multiple sclerosis.
    PLoS One. 2017;12:e0176519.
    PubMed     Abstract available

  175. IZQUIERDO G, Damas F, Paramo MD, Ruiz-Pena JL, et al
    The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.
    PLoS One. 2017;12:e0176174.
    PubMed     Abstract available

  176. CHARVET LE, Yang J, Shaw MT, Sherman K, et al
    Cognitive function in multiple sclerosis improves with telerehabilitation: Results from a randomized controlled trial.
    PLoS One. 2017;12:e0177177.
    PubMed     Abstract available

  177. MOLLISON D, Sellar R, Bastin M, Mollison D, et al
    The clinico-radiological paradox of cognitive function and MRI burden of white matter lesions in people with multiple sclerosis: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0177727.
    PubMed     Abstract available

  178. MCGINNIS RS, Mahadevan N, Moon Y, Seagers K, et al
    A machine learning approach for gait speed estimation using skin-mounted wearable sensors: From healthy controls to individuals with multiple sclerosis.
    PLoS One. 2017;12:e0178366.
    PubMed     Abstract available

  179. PARDO E, Carcamo C, Uribe-San Martin R, Ciampi E, et al
    Galectin-8 as an immunosuppressor in experimental autoimmune encephalomyelitis and a target of human early prognostic antibodies in multiple sclerosis.
    PLoS One. 2017;12:e0177472.
    PubMed     Abstract available

  180. LANDI D, Albanese M, Buttari F, Monteleone F, et al
    Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study.
    PLoS One. 2017;12:e0165415.
    PubMed     Abstract available

  181. RIGHART R, Schmidt P, Dahnke R, Biberacher V, et al
    Volume versus surface-based cortical thickness measurements: A comparative study with healthy controls and multiple sclerosis patients.
    PLoS One. 2017;12:e0179590.
    PubMed     Abstract available

  182. BERNITSAS E, Khan O, Razmjou S, Tselis A, et al
    Cerebrospinal fluid humoral immunity in the differential diagnosis of multiple sclerosis.
    PLoS One. 2017;12:e0181431.
    PubMed     Abstract available

  183. ITOH Y, Voskuhl RR
    Cell specificity dictates similarities in gene expression in multiple sclerosis, Parkinson's disease, and Alzheimer's disease.
    PLoS One. 2017;12:e0181349.
    PubMed     Abstract available

  184. BSTEH G, Ehling R, Walchhofer LM, Hegen H, et al
    Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis-The PaSiMS II study.
    PLoS One. 2017;12:e0181458.
    PubMed     Abstract available

  185. KIM HH, Jeong IH, Hyun JS, Kong BS, et al
    Metabolomic profiling of CSF in multiple sclerosis and neuromyelitis optica spectrum disorder by nuclear magnetic resonance.
    PLoS One. 2017;12:e0181758.
    PubMed     Abstract available

  186. WURTH S, Kuenz B, Bsteh G, Ehling R, et al
    Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study.
    PLoS One. 2017;12:e0182462.
    PubMed     Abstract available

  187. MESSINA S, Solaro C, Righini I, Bergamaschi R, et al
    Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).
    PLoS One. 2017;12:e0180651.
    PubMed     Abstract available

  188. ABDELHAK A, Hottenrott T, Mayer C, Hintereder G, et al
    CSF profile in primary progressive multiple sclerosis: Re-exploring the basics.
    PLoS One. 2017;12:e0182647.
    PubMed     Abstract available

  189. THALER C, Schneider T, Sedlacik J, Kutzner D, et al
    T1w dark blood imaging improves detection of contrast enhancing lesions in multiple sclerosis.
    PLoS One. 2017;12:e0183099.
    PubMed     Abstract available

  190. MODICA CM, Schweser F, Sudyn ML, Bertolino N, et al
    Effect of teriflunomide on cortex-basal ganglia-thalamus (CxBGTh) circuit glutamatergic dysregulation in the Theiler's Murine Encephalomyelitis Virus mouse model of multiple sclerosis.
    PLoS One. 2017;12:e0182729.
    PubMed     Abstract available

  191. MOROSO A, Ruet A, Lamargue-Hamel D, Munsch F, et al
    Microstructural analyses of the posterior cerebellar lobules in relapsing-onset multiple sclerosis and their implication in cognitive impairment.
    PLoS One. 2017;12:e0182479.
    PubMed     Abstract available

  192. CEUNINCK VAN CAPELLE A, Meide HV, Vosman FJH, Visser LH, et al
    A qualitative study assessing patient perspectives in the process of decision-making on disease modifying therapies (DMT's) in multiple sclerosis (MS).
    PLoS One. 2017;12:e0182806.
    PubMed     Abstract available

  193. PUTHENPARAMPIL M, Federle L, Poggiali D, Miante S, et al
    Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis.
    PLoS One. 2017;12:e0183957.
    PubMed     Abstract available

  194. MASUDA H, Hirano S, Takahashi N, Hatsugano E, et al
    Comparison of cognitive and brain grey matter volume profiles between multiple sclerosis and neuromyelitis optica spectrum disorder.
    PLoS One. 2017;12:e0184012.
    PubMed     Abstract available

  195. PARK HY, Park JW, Song HJ, Sohn HS, et al
    The Association between Polypharmacy and Dementia: A Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in South Korea.
    PLoS One. 2017;12:e0169463.
    PubMed     Abstract available

  196. TALMAGE GD, Coppes OJM, Javed A, Bernard J, et al
    Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study.
    PLoS One. 2017;12:e0173299.
    PubMed     Abstract available

  197. ZAPRUTKO T, Kopciuch D, Kus K, Merks P, et al
    Affordability of medicines in the European Union.
    PLoS One. 2017;12:e0172753.
    PubMed     Abstract available

  198. PAUZUOLIS M, Eich T, Burman J
    Quantification of gammadelta T cells and HLA-DR+ NK cells does not predict emergence of new contrast enhancing lesions in MS patients suspending natalizumab treatment.
    PLoS One. 2017;12:e0179095.
    PubMed     Abstract available

  199. CHAMI M, Halmer R, Schnoeder L, Anne Becker K, et al
    Acid sphingomyelinase deficiency enhances myelin repair after acute and chronic demyelination.
    PLoS One. 2017;12:e0178622.
    PubMed     Abstract available

  200. ALSOP J, Medin J, Cornelissen C, Vormfelde SV, et al
    Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL.
    PLoS One. 2017;12:e0173353.
    PubMed     Abstract available

  201. TAKAYASU L, Suda W, Watanabe E, Fukuda S, et al
    A 3-dimensional mathematical model of microbial proliferation that generates the characteristic cumulative relative abundance distributions in gut microbiomes.
    PLoS One. 2017;12:e0180863.
    PubMed     Abstract available

  202. JONAS SF, Mbogning C, Hassler S, Broet P, et al
    A score test for comparing cross-sectional survival data with a fraction of non-susceptible patients and its application in clinical immunology.
    PLoS One. 2017;12:e0179896.
    PubMed     Abstract available

  203. KIDD T, Carey N, Mold F, Westwood S, et al
    A systematic review of the effectiveness of self-management interventions in people with multiple sclerosis at improving depression, anxiety and quality of life.
    PLoS One. 2017;12:e0185931.
    PubMed     Abstract available

  204. FERNANDEZ O, Duran E, Ayuso T, Hernandez L, et al
    Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study).
    PLoS One. 2017;12:e0185766.
    PubMed     Abstract available

  205. FAVARETTO A, Lazzarotto A, Riccardi A, Pravato S, et al
    Enlarged Virchow Robin spaces associate with cognitive decline in multiple sclerosis.
    PLoS One. 2017;12:e0185626.
    PubMed     Abstract available

  206. BESELER C, Vollmer T, Graner M, Yu X, et al
    The complex relationship between oligoclonal bands, lymphocytes in the cerebrospinal fluid, and immunoglobulin G antibodies in multiple sclerosis: Indication of serum contribution.
    PLoS One. 2017;12:e0186842.
    PubMed     Abstract available

  207. RAKNES G, Smabrekke L
    Low dose naltrexone in multiple sclerosis: Effects on medication use. A quasi-experimental study.
    PLoS One. 2017;12:e0187423.
    PubMed     Abstract available

  208. WYBRECHT D, Reuter F, Pariollaud F, Zaaraoui W, et al
    New brain lesions with no impact on physical disability can impact cognition in early multiple sclerosis: A ten-year longitudinal study.
    PLoS One. 2017;12:e0184650.
    PubMed     Abstract available

  209. LIU S, Liu X, Chen S, Xiao Y, et al
    Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials.
    PLoS One. 2017;12:e0188644.
    PubMed     Abstract available

  210. MOISSET X, Perie M, Pereira B, Dumont E, et al
    Decreased prevalence of cancer in patients with multiple sclerosis: A case-control study.
    PLoS One. 2017;12:e0188120.
    PubMed     Abstract available

  211. GROBELNY A, Behrens JR, Mertens S, Otte K, et al
    Maximum walking speed in multiple sclerosis assessed with visual perceptive computing.
    PLoS One. 2017;12:e0189281.
    PubMed     Abstract available

  212. WEN J, Yablonskiy DA, Salter A, Cross AH, et al
    Limbic system damage in MS: MRI assessment and correlations with clinical testing.
    PLoS One. 2017;12:e0187915.
    PubMed     Abstract available

  213. CHEN Y, Zhen W, Guo T, Zhao Y, et al
    Histamine Receptor 3 negatively regulates oligodendrocyte differentiation and remyelination.
    PLoS One. 2017;12:e0189380.
    PubMed     Abstract available

    January 2016
  214. OBERT D, Helms G, Sattler MB, Jung K, et al
    Brain Metabolite Changes in Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: A Two-Year Follow-Up Study.
    PLoS One. 2016;11:e0162583.
    PubMed     Abstract available

  215. SOLARO C, Trabucco E, Signori A, Martinelli V, et al
    Depressive Symptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An Italian Multi-Center Study Using the Beck Depression Inventory.
    PLoS One. 2016;11:e0160261.
    PubMed     Abstract available

  216. TSIVGOULIS G, Katsanos AH, Mavridis D, Grigoriadis N, et al
    The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials.
    PLoS One. 2016;11:e0163296.
    PubMed     Abstract available

  217. MONTI MC, Guido D, Montomoli C, Sardu C, et al
    Is Geo-Environmental Exposure a Risk Factor for Multiple Sclerosis? A Population-Based Cross-Sectional Study in South-Western Sardinia.
    PLoS One. 2016;11:e0163313.
    PubMed     Abstract available

  218. JERNAS L, Wencel J, Wiak A, Bieniek M, et al
    Risk Factors for Poor Adherence to Betaferon(R) Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome.
    PLoS One. 2016;11:e0157950.
    PubMed     Abstract available

  219. KAUSHIK DK, Yong HY, Hahn JN, Silva C, et al
    Evaluating Soluble EMMPRIN as a Marker of Disease Activity in Multiple Sclerosis: Studies of Serum and Cerebrospinal Fluid.
    PLoS One. 2016;11:e0163802.
    PubMed     Abstract available

  220. RIEMANN-LORENZ K, Eilers M, von Geldern G, Schulz KH, et al
    Dietary Interventions in Multiple Sclerosis: Development and Pilot-Testing of an Evidence Based Patient Education Program.
    PLoS One. 2016;11:e0165246.
    PubMed     Abstract available

  221. KALRON A, Givon U, Frid L, Dolev M, et al
    Static Posturography and Falls According to Pyramidal, Sensory and Cerebellar Functional Systems in People with Multiple Sclerosis.
    PLoS One. 2016;11:e0164467.
    PubMed     Abstract available

  222. HAJIEBRAHIMI M, Montgomery S, Burkill S, Bahmanyar S, et al
    Risk of Premenopausal and Postmenopausal Breast Cancer among Multiple Sclerosis Patients.
    PLoS One. 2016;11:e0165027.
    PubMed     Abstract available

  223. KREMER IE, Evers SM, Jongen PJ, van der Weijden T, et al
    Identification and Prioritization of Important Attributes of Disease-Modifying Drugs in Decision Making among Patients with Multiple Sclerosis: A Nominal Group Technique and Best-Worst Scaling.
    PLoS One. 2016;11:e0164862.
    PubMed     Abstract available

  224. BACHELET D, Hassler S, Mbogning C, Link J, et al
    Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.
    PLoS One. 2016;11:e0162752.
    PubMed     Abstract available

  225. ALROUGHANI R, Akhtar S, Ahmed S, Behbehani R, et al
    Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?
    PLoS One. 2016;11:e0165846.
    PubMed     Abstract available

  226. DOBSON R, Ramagopalan S, Topping J, Smith P, et al
    A Risk Score for Predicting Multiple Sclerosis.
    PLoS One. 2016;11:e0164992.
    PubMed     Abstract available

  227. ZHANG L, Wang L, Tian P, Tian S, et al
    Identification of Genes Discriminating Multiple Sclerosis Patients from Controls by Adapting a Pathway Analysis Method.
    PLoS One. 2016;11:e0165543.
    PubMed     Abstract available

  228. MARTIN P, McGovern A, Massey J, Schoenfelder S, et al
    Identifying Causal Genes at the Multiple Sclerosis Associated Region 6q23 Using Capture Hi-C.
    PLoS One. 2016;11:e0166923.
    PubMed     Abstract available

  229. JOHNSON TW, Wu Y, Nathoo N, Rogers JA, et al
    Gray Matter Hypoxia in the Brain of the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis.
    PLoS One. 2016;11:e0167196.
    PubMed     Abstract available

  230. PIVOT D, Debouverie M, Grzebyk M, Brassat D, et al
    Geographical Heterogeneity of Multiple Sclerosis Prevalence in France.
    PLoS One. 2016;11:e0167556.
    PubMed     Abstract available

  231. PROSPERINI L, de Rossi N, Scarpazza C, Moiola L, et al
    Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.
    PLoS One. 2016;11:e0168376.
    PubMed     Abstract available

  232. BLOCK VA, Pitsch E, Tahir P, Cree BA, et al
    Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review.
    PLoS One. 2016;11:e0154335.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.